logo-loader
viewHemoGenyx Pharmaceuticals

Major Honour for HemoGenyx

Co-founder of New York-based company HemoGenyx Alexis Sandler tells Proactive how thrilled she was to welcome the Lt.Gov of New York to the HemoGenyx laboratories recently. The Lt.Governor met with their eminent team of scientists and saw first hand why HemoGenyx is described as a 'success story', originally invested in by the state of New York. Not only was this a major honour for HemoGenyx, this is an important step in consolidating the company's relationship with the state of New York.

Quick facts: HemoGenyx Pharmaceuticals

Price: 1.9 GBX

LSE:HEMO
Market: LSE
Market Cap: £6.86 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of HemoGenyx Pharmaceuticals named herein, including the promotion by the Company of HemoGenyx Pharmaceuticals in any Content on the Site, the...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

HemoGenyx CEO 'overwhelmed' by speed of progress at the company

Dr Vladislav Sandler, chief executive of HemoGenyx Pharmaceuticals PLC (LON:HEMO), caught up with Proactive's Andrew Scott while in London to meet with investors. It's been nearly nine months now since the company first listed in London and in that time they've inked four collaborations...

on 27/6/18

2 min read